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RADIOGRAPHIC ATLAS
Roy D. Altman
OARSI produced a Radiographic Atlas for Osteoarthritis of the
Hand, Hip, and Knee as a supplement to Osteoarthritis and Car-
tilage in 1995. The atlas has had considerable use by individuals
and in clinical trials. Despite being out of print, the atlas is still in
demand.
Objective: Produce a radiographic atlas as a supplement to
Osteoarthritis and Cartilage that will replace and improve on the
1995 images. A secondary objective is to have the atlas available
in an electronic format.
Method: The 1995 atlas was reviewed for the images most use-
ful for clinical trials. Replacement images were selected from
the Stanford University picture archive and communications sys-
tem (PACS) by reviewing consecutive radiographs obtained from
patients. Selected images were downloaded without patient iden-
tification information. Images were organized by hand, hip and
knee. They were reviewed for findings of osteoarthritis and im-
ages grouped into power point files by individual findings and
degree of change. Both investigators individually selected the
most promising images. Final images were selected by consen-
sus. Original electronic images were then cropped and placed in
sequence.
Results: Individual radiographic features (eg. osteophytes, joint
space narrowing) were recorded for hand (DIP, PIP, 1st CMC),
hip (acetabular, femoral) and knee (medial compartment, lateral
compartment, tibial, femoral); they were also sequenced for
normal, 1+, 2+, and 3+ change. Images were available in print
and electronic formats.
Conclusion: A radiographic atlas for osteoarthritis of the hand,
hip and knee was produced for use in clinical practice or clinical
trials.
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HISTOPATHOLOGY
Thomas Aigner
Established and broadly accepted histopathological criteria for
grading and staging of osteoarthritic changes in the human as
well as in animal models of cartilage degeneration is an impor-
tant step in OA research. This is needed in order to allow for
the comparability of studies performed in different places round
the world. OARSI has taken this challenge and established a
"Committee for the establishment of histopathology criteria for
animal models" consisting of different sub-committees for differ-
ent species. In principal and practice, every expert is welcome to
contribute his experience. First proposals for grading and scoring
systems will be introduced and will be open for discussion.
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EVALUATION AND VALIDATION OF MICROARRAY DATA
IN OSTEOARTHRITIS AND CARTILAGE RESEARCH
Thomas Aigner, Ralf Zimmer
Large-scale gene expression analysis became an important ex-
perimental tool in cartilage and OA research over the last years.
Whereas this approach clearly generated more and more large
data sets, the difficulties related to the validation and evaluation
of the obtained information remained enormous. This workshop
will introduce the topics and issues of large scale gene expres-
sion profiling focussing on biostatistic and bioinformatic issues.
It will show examples how data analysis can be performed and
how important biostatistical and bioinformatical are in order to
obtain reasonable results.
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TRASCRIPTIONAL REGULATION OF CHONDROCYTE
GENE EXPRESSION
Linda Sandell
Extracellular matrix metabolism plays a central role in develop-
ment of skeletal tissues and in most orthopaedic diseases and
trauma such as fracture or osteotomy repair, arthritis, cartilage,
repair and congenital skeletal deformity. During development or
diseases, specific genes must be expressed in order to make
or repair appropriate extracellular matrix. For example, specific
gene expression patterns are characteristic of bone and car-
tilage. The precise expression pattern depends on ta balance
of positive and negative transcription factors, proteins that con-
trol the synthesis of mRNA from the specific gene. In cartilage,
a number of studies indicate that Sox transcription factors are
critical positive regulators in genes such as COL2A1 COL0A2,
CoOL11A2, aggrecan and CD-RAP. In addition negative regu-
lators are also essential to fine tune gene regulation in chon-
drocytes and to turn of gene expression in non-cartilaginous
tissues. Negative transcription factors in cartilage included ∂EF-
1, snail/slug, CYRBP1, NT2 and C/EBP. Runs2 and osterix are
critical transcription factors for osteogenesis but also have some
influence on chondrogenesis. The availability of cis-regulatory
sites in specific genes combined with the availability of tran-
scription factors in the nucleus determines the level of gene
expression. Lastly, the selection of protein splice forms is made
at the level of nuclear processing of the precursor transcript in
the nucleus and is coupled to gene transcription.
7
THE INTERNATIONAL GROWTH OF JOINT
REPLACEMENT: DEVICES AND DEMOGRAPHICS
Thomas Parker Vail
While the growth in the number of total joint procedures world-
wide is not disputed, there exists a large regional variation in
the number of procedures performed per 1000 persons across
countries and continents. In the United Kingdom, it is esti-
mated that in 2006 almost 10% of the population over 65
years of age will receive a hip or knee replacement. In the
United States and Canada, the number approaches 10% for
hip replacement and over 14% for knee replacement proce-
dures. In contrast, less than 5% of the over 65 population in
the Baltic States, Poland, Russia, Greece, Turkey, Israel, Egypt,
and Japan (among others) will receive a hip or knee replace-
ment. More astounding is the fact that even in the countries
with the highest utilization, it is estimated that the procedures
are offered to only a fraction of the people who could ben-
efit. Not only is it interesting to consider the factors that are
driving the need for these procedures, but also the reason for
the variation. There is no question that economics are a major
factor, but other factors that explain variation include availability
of devices and surgeons, fear and lack of patient education,
and insufficient cost/benefit analysis to drive health policy deci-
sions.
